弹簧圈、AVP与MVP栓塞后肺动静脉畸形持续存在的回顾性倾向评分加权比较
本回顾性研究纳入112例患者共393个肺动静脉畸形(PAVM),比较弹簧圈、Amplatzer血管塞(AVP)和Micro Vascular Plug(MVP)栓塞后PAVM持续存在的风险,采用倾向评分加权校正选择偏倚。中位随访1.5年,总体持续存在率为10%,弹簧圈组16%、AVP组8%、MVP组0%。以弹簧圈为参照,MVP持续存在风险显著更低(HR < 0.01,p < .001),AVP风险亦较低(HR 0.37,p = .03)。
要点
- MVP栓塞后PAVM持续存在率为0%,显著低于弹簧圈(16%)和AVP(8%)。
- 随访肺CTA示PAVM持续存在定义为瘤囊缩小<70%或瘤囊对比剂强化。
- 倾向评分加权后,MVP和AVP持续存在风险均显著低于弹簧圈。
关键影像表现/征象
- PAVM持续存在定义为随访肺CTA上瘤囊缩小<70%或瘤囊对比剂强化。
- 中位随访1.5年(IQR 0.3-5.6年),总体持续存在率10%(41/393)。
- 弹簧圈组持续存在率16%(34/207),AVP组8%(7/88),MVP组0%(0/98)。
诊断标准与关键数值
- PAVM持续存在标准:随访肺CTA示瘤囊缩小<70%或瘤囊对比剂强化。
- 以弹簧圈为参照,MVP持续存在风险HR < 0.01(95% CI < 0.01至< 0.01,p < .001)。
- 以弹簧圈为参照,AVP持续存在风险HR 0.37(95% CI 0.16-0.90,p = .03)。
临床应用与阅片要点
- 随访肺CTA评估PAVM栓塞效果时,需关注瘤囊缩小程度和对比剂强化。
- MVP可作为PAVM栓塞的首选装置,优于弹簧圈和覆膜塞。
局限性
- 回顾性研究设计。
- 单中心研究。
- 装置选择存在偏倚,虽采用倾向评分加权校正,但权重后仍有喂养动脉直径不平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Endovascular embolization of pulmonary arteriovenous malformations (PAVMs) was historically performed with embolic coils. The Amplatzer Vascular Plug device (AVP) was introduced for this purpose in 2007 and the Micro Vascular Plug device (MVP) in 2013. OBJECTIVE. The purpose of this study was to compare coils, AVPs, and MVPs in terms of risk of persistence after PAVM embolization by use of propensity score weighting to account for biases in device selection. METHODS. This retrospective study included 112 patients (78 women and girls, 34 men and boys; mean age, 45 years) who underwent embolization of 393 PAVMs with a single device type (coil, MVP, or AVP) from January 2003 to January 2020. Persistence was defined as less than 70% reduction in PAVM sac size or contrast enhancement of the sac on follow-up pulmonary CTA. A Cox proportional hazards regression model was used to assess associations between embolic device selection and PAVM persistence. Inverse propensity score weighting was used to account for differences in embolic device selection based on patient and PAVM characteristics. RESULTS. The median postembolization follow-up period was 1.5 years (IQR, 0.3-5.6 years). Persistence was found in 10% (41/393) of PAVMs, including 16% (34/207) of those treated with coils, 8% (7/88) of those treated with AVPs, and 0% (0/98) of those treated with MVPs. Variables associated with embolization device (p < .25) were age, sex, pediatric versus adult status, smoking status, PAVM complexity, PAVM laterality, number of feeding arteries, and feeding artery diameter. The Cox regression model incorporated inverse propensity score weighting to account for the differences between treatment groups in these variables and incorporated feeding artery diameter because of imbalance remaining after weighting. With coils as the referent, MVPs had a hazard ratio for persistence of less than 0.01 (95% CI, < 0.01 to < 0.01; p < .001), and AVPs had a hazard ratio of 0.37 (95% CI, 0.16-0.90; p = .03). CONCLUSION. The risk of persistence after PAVM embolization was significantly lower for MVPs alone than for coils or AVPs alone. In addition, the risk of persistence was lower for AVPs than for coils. CLINICAL IMPACT. The findings support the clinical use of MVPs as the preferred device for PAVM embolization over coils and polytetrafluoroethylene-covered plugs.
引用
- Latif, Bailey, Motaghi, et al. Postembolization Persistence of Pulmonary Arteriovenous Malformations: A Retrospective Comparison of Coils and Amplatzer and Micro Vascular Plugs Using Propensity Score Weighting. AJR Am J Roentgenol. 2022. PMID: 35946857. doi:10.2214/AJR.21.27218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。